Another recent work carried out in a large cohort of NSCLC patients showed that sPD1 levels were significantly associated with better OS after 6 weeks of treatment in patients under anti-PD1 therapy alone (38) confirming that the increase of this molecule was correlated to a better prognosis probably blocking the ligation between PD1 and PDL1 expressed by cells. Here, HOXD13 is linked to non-small cell lung carcinoma.